Immunologic Research

, Volume 56, Issue 1, pp 163–171

The immunology of Leishmania/HIV co-infection

Article

Abstract

Leishmaniases are emerging as an important disease in human immunodeficiency virus (HIV)–infected persons living in several sub-tropical and tropical regions around the world, including the Mediterranean. The HIV/AIDS pandemic is spreading at an alarming rate in Africa and the Indian subcontinent, areas with very high prevalence of leishmaniases. The spread of HIV into rural areas and the concomitant spread of leishmaniases to suburban/urban areas have helped maintain the occurrence of Leishmania/HIV co-infection in many parts of the world. The number of cases of Leishmania/HIV co-infection is expected to rise owing to the overlapping geographical distribution of the two infections. In Southwestern Europe, there is also an increasing incidence of Leishmania/HIV co-infection (particularly visceral leishmaniasis) in such countries as France, Italy, Spain and Portugal. Studies suggest that in humans, very complex mechanisms involving dysregulation of host immune responses contribute to Leishmania-mediated immune activation and pathogenesis of HIV. In addition, both HIV-1 and Leishmania infect and multiply within cells of myeloid or lymphoid origin, thereby presenting a perfect recipe for reciprocal modulation of Leishmania and HIV-1-related disease pathogenesis. Importantly, because recovery from leishmaniases is associated with long-term persistence of parasites at the primary infection sites and their draining lymph nodes, there is very real possibility that HIV-mediated immunosuppression (due to CD4+ T cell depletion) could lead to reactivation of latent infections (reactivation leishmaniasis) in immunocompromised patients. Here, we present an overview of the immunopathogenesis of Leishmania/HIV co-infection and the implications of this interaction on Leishmania and HIV disease outcome.

Keywords

Leishmania Leishmaniasis Human immunodeficiency virus (HIV) Acquired immunodeficiency syndrome (AIDS) Co-infection Reactivation leishmaniasis 

References

  1. 1.
    Alvar J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE. 2012;7(5):e35671.PubMedCrossRefGoogle Scholar
  2. 2.
    Kamhawi S. The biological and immunomodulatory properties of sand fly saliva and its role in the establishment of Leishmania infections. Microbes Infect. 2000;2(14):1765–73.PubMedCrossRefGoogle Scholar
  3. 3.
    Molina R, Gradoni L, Alvar J. HIV and the transmission of Leishmania. Ann Trop Med Parasitol. 2003;97(Suppl 1):29–45.PubMedCrossRefGoogle Scholar
  4. 4.
    Mougneau E, Bihl F, Glaichenhaus N. Cell biology and immunology of Leishmania. Immunol Rev. 2011;240(1):286–96.PubMedCrossRefGoogle Scholar
  5. 5.
    Melby PC. Vaccination against cutaneous leishmaniasis: current status. Am J Clin Dermatol. 2002;3(8):557–70.PubMedCrossRefGoogle Scholar
  6. 6.
    Scott P, et al. The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development. Immunol Rev. 2004;201:318–38.PubMedCrossRefGoogle Scholar
  7. 7.
    Bailey MS, Lockwood DN. Cutaneous leishmaniasis. Clin Dermatol. 2007;25(2):203–11.PubMedCrossRefGoogle Scholar
  8. 8.
    WHO. HIV/AIDS Fact Sheet. 2012 cited 2012; Available from: http://www.who.int/mediacentre/factsheets/fs360/en/index.html.
  9. 9.
    Dougan S, et al. HIV in gay and bisexual men in the United Kingdom: 25 years of public health surveillance. Epidemiol Infect. 2008;136(2):145–56.PubMedCrossRefGoogle Scholar
  10. 10.
    Centre for Disease Control. Kaposi’s sarcoma and pneumocystis pneumonia among homosexual men- New York City and California. Morb Mortal Wkly Rep. 1981;3.Google Scholar
  11. 11.
    Hymes KB, et al. Kaposi’s sarcoma in homosexual men-a report of eight cases. Lancet. 1981;2(8247):598–600.PubMedCrossRefGoogle Scholar
  12. 12.
    Greene WC. A history of AIDS: looking back to see ahead. Eur J Immunol. 2007;37(Suppl 1):S94–102.PubMedCrossRefGoogle Scholar
  13. 13.
    UNAIDS. Global report: UNAIDS Report on Global AIDS Epidemic. 2012.Google Scholar
  14. 14.
    Ray N, Doms RW. HIV-1 coreceptors and their inhibitors. Curr Top Microbiol Immunol. 2006;303:97–120.PubMedCrossRefGoogle Scholar
  15. 15.
    Greene WC, Peterlin BM. Charting HIV’s remarkable voyage through the cell: basic science as a passport to future therapy. Nat Med. 2002;8(7):673–80.PubMedCrossRefGoogle Scholar
  16. 16.
    Schroder AR, et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 2002;110(4):521–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Garrus JE, et al. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell. 2001;107(1):55–65.PubMedCrossRefGoogle Scholar
  18. 18.
    Cruz I, et al. Leishmania/HIV co-infections in the second decade. Indian J Med Res. 2006;123(3):357–88.PubMedGoogle Scholar
  19. 19.
    Desjeux P, Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol. 2003;97(Suppl 1):3–15.PubMedCrossRefGoogle Scholar
  20. 20.
    Sinha PK, et al. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis. 2011;53(7):e91–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Diro A, Hailu A, Lynen L. VL-HIV co-infection in East-Africa: current challenges and perspectives. In: 7th European congress on tropical medicine and international health. Barcelona, Spain; 2011.Google Scholar
  22. 22.
    Chicharro C, Alvar J. Lower trypanosomatids in HIV/AIDS patients. Ann Trop Med Parasitol. 2003;97(Suppl 1):75–8.PubMedCrossRefGoogle Scholar
  23. 23.
    WHO. Leishmania/HIV co-infection in south-western Europe 1990–1998: a retrospective analysis f 965 cases. Geneva: World Health Orginization; 2000. p. 14.Google Scholar
  24. 24.
    Alvar J, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev. 1997;10(2):298–319.PubMedGoogle Scholar
  25. 25.
    Alvar J, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008;21(2):334–59. table of contents.PubMedCrossRefGoogle Scholar
  26. 26.
    Alvar J, et al. AIDS and Leishmania infantum. New approaches for a new epidemiological problem. Clin Dermatol. 1996;14(5):541–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Hotez PJ, et al. Combating tropical infectious diseases: report of the Disease Control Priorities in Developing Countries Project. Clin Infect Dis. 2004;38(6):871–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Bern C, Chowdhury R. The epidemiology of visceral leishmaniasis in Bangladesh: prospects for improved control. Indian J Med Res. 2006;123(3):275–88.PubMedGoogle Scholar
  29. 29.
    Joshi DD, Sharma M, Bhandari S. Visceral leishmaniasis in Nepal during 1980–2006. J Commun Dis. 2006;38(2):139–48.PubMedGoogle Scholar
  30. 30.
    Schenkel K, et al. Visceral leishmaniasis in southeastern Nepal: a cross-sectional survey on Leishmania donovani infection and its risk factors. Trop Med Int Health. 2006;11(12):1792–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Singh SP, et al. Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India. Trop Med Int Health. 2006;11(6):899–905.PubMedCrossRefGoogle Scholar
  32. 32.
    UNAIDS. Global Report: UNAIDS Report on Global AIDS Epidemic. 2010.Google Scholar
  33. 33.
    UNAIDS. Global Report: UNIADS Report on Global AIDS Epidemic. 2009.Google Scholar
  34. 34.
    Singh S, et al. A new focus of visceral leishmaniasis in sub-Himalayan (Kumaon) region of northern India. J Commun Dis. 1999;31(2):73–7.PubMedGoogle Scholar
  35. 35.
    Gurubacharya RL, et al. Prevalence of visceral leishmania and HIV co-infection in Nepal. Indian J Med Res. 2006;123(3):473–5.PubMedGoogle Scholar
  36. 36.
    Guiguemde RT, et al. Leishmania major and HIV co-infection in Burkina Faso. Trans R Soc Trop Med Hyg. 2003;97(2):168–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Couppie P, et al. Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana. Br J Dermatol. 2004;151(6):1165–71.PubMedCrossRefGoogle Scholar
  38. 38.
    Lyons S, Veeken H, Long J. Visceral leishmaniasis and HIV in Tigray, Ethiopia. Trop Med Int Health. 2003;8(8):733–9.PubMedCrossRefGoogle Scholar
  39. 39.
    UNAIDS/WHO. UNAIDS/WHO AIDS Epidemic Updates. 2005.Google Scholar
  40. 40.
    Ngouateu OB, et al. Clinical features and epidemiology of cutaneous leishmaniasis and Leishmania major/HIV co-infection in Cameroon: results of a large cross-sectional study. Trans R Soc Trop Med Hyg. 2012;106(3):137–42.PubMedCrossRefGoogle Scholar
  41. 41.
    WHO. Report of the fifth consultative meeting on Leishmania/HIV coinfection, 2007: Addis Ababa, Ethiopia.Google Scholar
  42. 42.
    Daher EF, et al. Clinical and epidemiological features of visceral leishmaniasis and HIV co-infection in fifteen patients from Brazil. J Parasitol. 2009;95(3):652–5.PubMedCrossRefGoogle Scholar
  43. 43.
    Nascimento ET, et al. The emergence of concurrent HIV-1/AIDS and visceral leishmaniasis in Northeast Brazil. Trans R Soc Trop Med Hyg. 2011;105(5):298–300.PubMedCrossRefGoogle Scholar
  44. 44.
    Orsini M, et al. High frequency of asymptomatic Leishmania spp. infection among HIV-infected patients living in endemic areas for visceral leishmaniasis in Brazil. Trans R Soc Trop Med Hyg. 2012;106(5):283–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Lindoso JAL. Visceral Leishmaniasis—HIV co-infection: emerging in South America. In: 7th European congress on tropical medicine and international health. Barcelona, Spain: Wiley Blackwell; 2011.Google Scholar
  46. 46.
    Bernier R, et al. Activation of human immunodeficiency virus type 1 in monocytoid cells by the protozoan parasite Leishmania donovani. J Virol. 1995;69(11):7282–5.PubMedGoogle Scholar
  47. 47.
    Bentwich Z. Concurrent infections that rise the HIV viral load. J HIV Ther. 2003;8(3):72–5.PubMedGoogle Scholar
  48. 48.
    Santos-Oliveira JR, et al. High levels of T lymphocyte activation in Leishmania-HIV-1 co-infected individuals despite low HIV viral load. BMC Infect Dis. 2010;10:358.PubMedCrossRefGoogle Scholar
  49. 49.
    Stebbing J, Gazzard B, Douek DC. Where does HIV live? N Engl J Med. 2004;350(18):1872–80.PubMedCrossRefGoogle Scholar
  50. 50.
    Murray HW, et al. Advances in leishmaniasis. Lancet. 2005;366(9496):1561–77.PubMedCrossRefGoogle Scholar
  51. 51.
    Garg R, Trudel N, Tremblay MJ. Consequences of the natural propensity of Leishmania and HIV-1 to target dendritic cells. Trends Parasitol. 2007;23(7):317–24.PubMedCrossRefGoogle Scholar
  52. 52.
    Kedzierska K, Crowe SM. The role of monocytes and macrophages in the pathogenesis of HIV-1 infection. Curr Med Chem. 2002;9(21):1893–903.PubMedCrossRefGoogle Scholar
  53. 53.
    Azzam R, et al. Impaired complement-mediated phagocytosis by HIV type-1-infected human monocyte-derived macrophages involves a cAMP-dependent mechanism. AIDS Res Hum Retroviruses. 2006;22(7):619–29.PubMedCrossRefGoogle Scholar
  54. 54.
    Kedzierska K, et al. Defective phagocytosis by human monocyte/macrophages following HIV-1 infection: underlying mechanisms and modulation by adjunctive cytokine therapy. J Clin Virol. 2003;26(2):247–63.PubMedCrossRefGoogle Scholar
  55. 55.
    Barreto-de-Souza V, et al. Increased Leishmania replication in HIV-1-infected macrophages is mediated by tat protein through cyclooxygenase-2 expression and prostaglandin E2 synthesis. J Infect Dis. 2006;194(6):846–54.PubMedCrossRefGoogle Scholar
  56. 56.
    Turco SJ. Adversarial relationship between the leishmania lipophosphoglycan and protein kinase C of host macrophages. Parasite Immunol. 1999;21(12):597–600.PubMedCrossRefGoogle Scholar
  57. 57.
    Garg R, et al. Leishmania infantum amastigotes enhance HIV-1 production in cocultures of human dendritic cells and CD4 T cells by inducing secretion of IL-6 and TNF-alpha. PLoS Negl Trop Dis. 2009;3(5):e441.PubMedCrossRefGoogle Scholar
  58. 58.
    Wolday D, et al. Role of Leishmania donovani and its lipophosphoglycan in CD4+ T-cell activation-induced human immunodeficiency virus replication. Infect Immun. 1999;67(10):5258–64.PubMedGoogle Scholar
  59. 59.
    Griffin GE, et al. Induction of NF-kappa B during monocyte differentiation is associated with activation of HIV-gene expression. Res Virol. 1991;142(2–3):233–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Bernier R, et al. The lipophosphoglycan of Leishmania donovani up-regulates HIV-1 transcription in T cells through the nuclear factor-kappaB elements. J Immunol. 1998;160(6):2881–8.PubMedGoogle Scholar
  61. 61.
    Wolday D, et al. Live and killed human immunodeficiency virus type-1 increases the intracellular growth of Leishmania donovani in monocyte-derived cells. Scand J Infect Dis. 1998;30(1):29–34.PubMedCrossRefGoogle Scholar
  62. 62.
    Zhao C, et al. In primary human monocyte-derived macrophages exposed to Human immunodeficiency virus type 1, does the increased intracellular growth of Leishmania infantum rely on its enhanced uptake? J Gen Virol. 2006;87(Pt 5):1295–302.PubMedCrossRefGoogle Scholar
  63. 63.
    Lopez-Velez R, et al. Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am J Trop Med Hyg. 1998;58(4):436–43.PubMedGoogle Scholar
  64. 64.
    Bossolasco S, et al. Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J Clin Microbiol. 2003;41(11):5080–4.PubMedCrossRefGoogle Scholar
  65. 65.
    Lindoso JA, et al. Unusual manifestations of tegumentary leishmaniasis in AIDS patients from the New World. Br J Dermatol. 2009;160(2):311–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Nylen S, Sacks D. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol. 2007;28(9):378–84.PubMedCrossRefGoogle Scholar
  67. 67.
    Owens BM, et al. IL-10-producing Th1 cells and disease progression are regulated by distinct CD11c(+) cell populations during visceral leishmaniasis. PLoS Pathog. 2012;8(7):e1002827.PubMedCrossRefGoogle Scholar
  68. 68.
    Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol. 1995;13:151–77.PubMedCrossRefGoogle Scholar
  69. 69.
    Afonso LC, Scott P. Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect Immun. 1993;61(7):2952–9.PubMedGoogle Scholar
  70. 70.
    Scott P, et al. Role of cytokines and CD4+ T-cell subsets in the regulation of parasite immunity and disease. Immunol Rev. 1989;112:161–82.PubMedCrossRefGoogle Scholar
  71. 71.
    Scott P. The role of TH1 and TH2 cells in experimental cutaneous leishmaniasis. Exp Parasitol. 1989;68(3):369–72.PubMedCrossRefGoogle Scholar
  72. 72.
    Scharton-Kersten T, et al. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol. 1995;154(10):5320–30.PubMedGoogle Scholar
  73. 73.
    Himmelrich H, et al. In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease. J Immunol. 2000;164(9):4819–25.PubMedGoogle Scholar
  74. 74.
    Tripathi P, Singh V, Naik S. Immune response to leishmania: paradox rather than paradigm. FEMS Immunol Med Microbiol. 2007;51(2):229–42.PubMedCrossRefGoogle Scholar
  75. 75.
    Wolday D, et al. HIV-1 inhibits Leishmania-induced cell proliferation but not production of interleukin-6 and tumour necrosis factor alpha. Scand J Immunol. 1994;39(4):380–6.PubMedCrossRefGoogle Scholar
  76. 76.
    Zijlstra EE, et al. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis. 2003;3(2):87–98.PubMedCrossRefGoogle Scholar
  77. 77.
    Wolday D, et al. HIV-1 alters T helper cytokines, interleukin-12 and interleukin-18 responses to the protozoan parasite Leishmania donovani. AIDS. 2000;14(8):921–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Nigro L, et al. In vitro production of type 1 and type 2 cytokines by peripheral blood mononuclear cells from subjects coinfected with human immunodeficiency virus and Leishmania infantum. Am J Trop Med Hyg. 1999;60(1):142–5.PubMedGoogle Scholar
  79. 79.
    Milano S, et al. IL-15 in human visceral leishmaniasis caused by Leishmania infantum. Clin Exp Immunol. 2002;127(2):360–5.PubMedCrossRefGoogle Scholar
  80. 80.
    d’Ettorre G, et al. Central role of interleukin-15 in human immunodeficiency virus (HIV)-infected patients with visceral leishmaniasis. Acta Trop. 2006;99(1):83–7.PubMedCrossRefGoogle Scholar
  81. 81.
    Olivier M, et al. The pathogenesis of Leishmania/HIV co-infection: cellular and immunological mechanisms. Ann Trop Med Parasitol. 2003;97(Suppl 1):79–98.PubMedCrossRefGoogle Scholar
  82. 82.
    Medrano FJ, et al. Dynamics of serum cytokines in patients with visceral leishmaniasis and HIV-1 co-infection. Clin Exp Immunol. 1998;114(3):403–7.PubMedCrossRefGoogle Scholar
  83. 83.
    Villanueva JL, et al. Prospective evaluation and follow-up of European patients with visceral leishmaniasis and HIV-1 coinfection in the era of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis. 2000;19(10):798–801.PubMedCrossRefGoogle Scholar
  84. 84.
    Lopez-Velez R. The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV. Ann Trop Med Parasitol. 2003;97(Suppl 1):143–7.PubMedCrossRefGoogle Scholar
  85. 85.
    Rosenthal E, et al. Declining incidence of visceral leishmaniasis in HIV-infected individuals in the era of highly active antiretroviral therapy. AIDS. 2001;15(9):1184–5.PubMedCrossRefGoogle Scholar
  86. 86.
    Tortajada C, et al. Highly active antiretroviral therapy (HAART) modifies the incidence and outcome of visceral leishmaniasis in HIV-infected patients. J Acquir Immune Defic Syndr. 2002;30(3):364–6.PubMedGoogle Scholar
  87. 87.
    Tumbarello M, et al. Highly active antiretroviral therapy decreases the incidence of visceral leishmaniasis in HIV-infected individuals. AIDS. 2000;14(18):2948–9.PubMedCrossRefGoogle Scholar
  88. 88.
    ter Horst R, et al. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis. 2008;46(11):1702–9.PubMedCrossRefGoogle Scholar
  89. 89.
    de Gaetano Donati K, et al. Effect of highly active antiretroviral therapy on the incidence of bacterial pneumonia in HIV-infected subjects. Int J Antimicrob Agents. 2000;16(3):357–60.PubMedCrossRefGoogle Scholar
  90. 90.
    de Gaetano Donati K, et al. Impact of highly active antiretroviral therapy (HAART) on the incidence of bacterial infections in HIV-infected subjects. J Chemother. 2003;15(1):60–5.PubMedGoogle Scholar
  91. 91.
    Albrecht H, et al. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS. 1998;12(10):1149–54.PubMedCrossRefGoogle Scholar
  92. 92.
    Durand I, et al. Disseminated cutaneous leishmaniasis revealing human immunodeficiency virus infection. Ann Dermatol Venereol. 1998;125(4):268–70.PubMedGoogle Scholar
  93. 93.
    Rueda CM, et al. HIV-induced T-cell activation/exhaustion in rectal mucosa is controlled only partially by antiretroviral treatment. PLoS ONE. 2012;7(1):e30307.PubMedCrossRefGoogle Scholar
  94. 94.
    Aebischer T, Moody SF, Handman E. Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host. Infect Immun. 1993;61(1):220–6.PubMedGoogle Scholar
  95. 95.
    Aebischer T. Recurrent cutaneous leishmaniasis: a role for persistent parasites? Parasitol Today. 1994;10(1):25–8.PubMedCrossRefGoogle Scholar
  96. 96.
    Engwerda CR, Ato M, Kaye PM. Macrophages, pathology and parasite persistence in experimental visceral leishmaniasis. Trends Parasitol. 2004;20(11):524–30.PubMedCrossRefGoogle Scholar
  97. 97.
    Berhe N, et al. Ethiopian visceral leishmaniasis patients co-infected with human immunodeficiency virus. Trans R Soc Trop Med Hyg. 1995;89(2):205–7.PubMedCrossRefGoogle Scholar
  98. 98.
    Berhe N, et al. HIV viral load and response to antileishmanial chemotherapy in co-infected patients. AIDS. 1999;13(14):1921–5.PubMedCrossRefGoogle Scholar
  99. 99.
    Wolday D, et al. Emerging Leishmania/HIV co-infection in Africa. Med Microbiol Immunol. 2001;190(1–2):65–7.PubMedGoogle Scholar
  100. 100.
    Saravia NG, et al. Recurrent lesions in human Leishmania braziliensis infection–reactivation or reinfection? Lancet. 1990;336(8712):398–402.PubMedCrossRefGoogle Scholar
  101. 101.
    Stenger S, et al. Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. J Exp Med. 1996;183(4):1501–14.PubMedCrossRefGoogle Scholar
  102. 102.
    Park AY, Hondowicz BD, Scott P. IL-12 is required to maintain a Th1 response during Leishmania major infection. J Immunol. 2000;165(2):896–902.PubMedGoogle Scholar
  103. 103.
    Cota GF, de Sousa MR, Rabello A. Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Neg Trop Dis. 2011;5(6):e1153.CrossRefGoogle Scholar
  104. 104.
    Aebischer T, Moody SF, Handman E. Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host. Infect Immun. 1993;61(1):220–6.PubMedGoogle Scholar
  105. 105.
    Belkaid Y, et al. CD4+ CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature. 2002;420(6915):502–7.PubMedCrossRefGoogle Scholar
  106. 106.
    Uzonna JE, et al. Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J Immunol. 2001;167(12):6967–74.PubMedGoogle Scholar
  107. 107.
    Klatt NR, et al. SIV infection of rhesus macaques results in dysfunctional T- and B-cell responses to neo and recall Leishmania major vaccination. Blood. 2011;118(22):5803–12.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Immunology and Medical Microbiology, Faculty of MedicineUniversity of ManitobaWinnipegCanada
  2. 2.Parasite Vaccines Development Laboratory, Department of Immunology, Faculty of MedicineUniversity of ManitobaWinnipegCanada
  3. 3.Department of Medical Microbiology, Faculty of MedicineUniversity of ManitobaWinnipegCanada

Personalised recommendations